Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01AG080652 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of California, Irvine | OTHER |
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
Not provided
Some types of meditation lead heart rate to become more steady as breathing quiets whereas others lead to large heart rate swings up and down (oscillations) as breathing becomes deeper and slower. The current study is designed to investigate how daily mindfulness practice with heart rate biofeedback during breathing in a pattern that either increases or decreases heart rate oscillation affect attention and memory and blood biomarkers associated with Alzheimer's disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Increase Oscillation | Experimental | Participants will breath at a slow "resonance" frequency during a breath-focused mindfulness practice and receive biofeedback to increase heart rate oscillation. |
|
| Decrease Oscillation | Experimental | Participants' breathing will not be fixed to particular frequency during a breath-focused mindfulness practice and they will receive biofeedback to decrease heart rate oscillation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Daily practice | Behavioral | Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in plasma amyloid-beta 42 levels | Plasma Ab42 levels will be compared for Week 1 (pre-intervention) and Week 10 (post-intervention). Investigators will test for a time X condition interaction in plasma Ab 42 levels (to assess group differences in change). | Week 1 and Week 10 |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma amyloid-beta 40 levels | Plasma Ab40 levels will be compared for Week 1 (pre-intervention) and Week 10 (post-intervention). Investigators will test for a time X condition interaction in plasma Ab 40 levels (to assess group differences in change). | Week 1 and Week 10 |
| Plasma Ab42/40 ratio |
| Measure | Description | Time Frame |
|---|---|---|
| Locus coeruleus (LC) responses to novel faces | Investigators will test for a time x condition interaction in phasic LC responses to novel faces during an fMRI face-name task. | Week 1 and Week 10 |
Inclusion criteria
Exclusion criteria
Have a disorder that would impede performing the breathing intervention (e.g., abnormal cardiac rhythm, arrhythmia, dyspnea)
Have cognitive impairment
Have regularly played Lumosity games in the past 6 months
Have any conditions listed below that are not safe for MRI
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emotion & Cognition Lab Coordinator | Contact | 213-740-9543 | matherlab@usc.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Southern California | Recruiting | Los Angeles | California | 90089 | United States |
All individual scores associated with the primary and secondary outcomes will be shared.
Functional and structural brain images will be shared. Lumosity game play data will be shared.
Not provided
IPD will be shared upon publication of results from those IPD with no end date.
The investigators plan to use Openneuro.org, but if options change, the investigators may select another database. The plan is to have the data shared at a repository where those who are interested can access it. At Openneuro.org, all data are freely available to all users.
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigators will test for a time X condition interaction with plasma Ab42/40 ratio values as the dependent variable (to assess group differences in change). |
| Week 1 and Week 10 |
| Plasma pTau-181/tTau ratio | Investigators will test for a time X condition interaction with the ratio of pTau-181 and total tau values as the dependent variable (to assess group differences in change). | Week 1 and Week 10 |
| Change in brain perivascular space volume | Investigators will test for a time X condition interaction in perivascular space volume. | Week 1 and Week 10 |
| Brain training performance on Lumosity games during the breathing intervention | Investigators will compute a general learning factor across performance on all games played daily during the intervention period (Weeks 2-10) and separately across performance on all games played daily before the intervention period (Week 1). Investigators will test for group differences in performance during the intervention, controlling for performance before the intervention. | During intervention (daily during Weeks 2-10) and before intervention (daily during Week 1) |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |